DPP4 and familial pancreatic carcinoma: In conclusion, use of CD26/DPP4 inhibitors is associated with improved survival outcomes in patients with prostate cancer but not in breast or pancreatic cancer patients, which may be linked to the protein expression profiling of CD26/DPP4 in these malignancies.